Background and Organization

Structure and governing bodies of the DKTK

The DKTK foundation was established on 18 October 2012. The supervising body of the DKTK foundation is the Board of Trustees, consisting of 8 members drawn from the DKTK’s funding bodies, i.e. one representative from the Federal Ministry of Education and Research (BMBF) and one representative from the research ministries of each of the participating federal states.

DKTK Foundation Council

The Board of Trustees supervises the legal compliance, expediency and economic viability of the foundation’s activities. It decides on the foundation’s general research aims and its research policy and financial matters. It also takes decisions on management and performance-monitoring principles and draws up multi-year budgets, including expansion and investment programs. The Board of Trustees usually meets twice a year.

Members of the Board of Trustees

  • Dr. Jan Grapentin Federal Ministry of Education and Research
  • Dr. Florian Leiner Bavarian State Ministry of Education, Cultural Affairs, Science and the Arts
  • Dr. Dorothee Lux Hessian Ministry for Science and the Arts
  • Dr. Björn Maul Senate Department for Economy, Energy and Public Enterprises
  • Dr. Beate Mueller Ministry for Innovation, Science and Research North Rhine-Westphalia
  • Dr. Karin Schwarzenbacher Ministry for Science and the Arts Baden-Wuerttemberg
  • Dr. Annerose Beck State Ministry for Science and the Arts Saxony
  • Dr. Andreas Gerhardt Ministry for Science and Health, Rhineland-Palatinate

DKTK Steering Committee

As the managing board and central managing body of the foundation, the Steering Committee manages the foundation’s activities. In particular, it has to ensure that the foundation accomplishes its mission continuously and sustainably. The Steering Committee consists of the DKFZ as the core center, and spokespersons from the translation centers. The Steering Committee meets at least once a month.

DKTK%20LA_2021_en.png

 

DKTK Scientific Advisory Board

The consortium’s scientific work is supervised by a Scientific Advisory Board consisting of leading international experts in the field of translational cancer research.

It advises the Board of Trustees and the Steering Committee on scientific issues, regularly gives its opinion on the scientific work of the translation centers and on their draft research and development programs, and is consulted on the selection of DKTK joint funding projects. The Scientific Advisory Board meets at least once a year.

Members of the DKTK Scientific Advisory Board and DKTK Steering Committee

© DKFZ/Jutta Jung

Lowest Row f. l. t. r.:

  • Prof. Dr. Wilko Weichert, Munich
  • Prof. Anne-Lise Børresen-Dale, Oslo
  • Prof. Elaine Mardis, Columbus, Ohio
  • Prof. Michael Baumann, Heidelberg

Second Row f. l. t. r.:

  • Prof. Angelika Eggert, Berlin
  • Prof. Carlos Caldas, Cambridge
  • Ursula Weyrich, Heidelberg
  • Prof. Christoph Peters, Freiburg

Third Row f. l. t. r.:

  • Prof. Mechthild Krause, Dresden
  • Prof. Kevin Brindle, Cambridge
  • Prof. Wolfgang Wick, Heidelberg
  • Prof. Sir Alex Markham, Leeds

Upper Row f. l. t. r.:

  • Prof. Hans-Georg Rammensee, Tübingen
  • Dr. Myriam Mendila, Basel
  • Prof. Hubert Serve, Frankfurt
  • Prof. Martin Schuler, Essen/Düsseldorf

Not in the Picture:

  • Prof. Ulrik Ringborg, Stockholm
  • Prof. Licia Rivoltini, Milano
  •  Prof. Jolanda de Vries, Nijmegen
  • Prof. Klaus Schulze-Osthoff, Tübingen
  • Prof. Amato Giaccia, Oxford
  • Prof. Holger Moch, Zurich

DKFZ Patient Advisory Council for Cancer Research

(v. l. oben n. r. unten) R. von Holtzbrinck, R. Haidinger, K. Arndt, J. Schmidt, R. Rambach, S. Houwaart, M. Roth, R. Hauke, M. Baumann, U. Roth, W. Hiddemann (© Uwe Anspach / DKFZ

Patients themselves can play a key role in successful research by helping to shape the conditions in which it takes place. In setting up the Patient Advisory Council, the German Cancer Research Center (DKFZ) and its clinical research networks in the National Center for Tumor Diseases (NCT) and the German Cancer Consortium (DKTK) aim to increase the inclusion of patient views in research projects and promote public understanding for modern cancer research.

 

 

 

 

The committee meets twice a year and advises the Management Board on the following topics from a patient perspective:

  • new ideas for cancer research
  • identification of unforeseen risks, obstacles and consequences of the DKFZ’s research strategies and projects
  • conditions for research in Germany
  • promotion of understanding and trust with regard to modern cancer research among the lay public and other non-scientific interest groups

Here you can find further, up-to-date information on the Patient Advisory Committee.